Immunic, Inc.: 5%+ holders

As of November 6, 2026, 13 holders' latest Schedule 13D or 13G filings report owning 5% or more of Immunic, Inc. The largest reported stake is Adage Capital Management, L.P.'s, at 9.99%. 33 filings are on record since July 31, 2025 (Schedule 13G/A, August 12, 2025).

Laurion Capital Management LP also filed stake reports on 2 other companies ↓

Sell to companies like Immunic, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-11-02 · Reporting person: Aberdeen Group plc · Sole voting: 0 · Shared voting: 1,090,427 · Sole dispositive: 0 · Shared dispositive: 1,090,427 · SCHEDULE 13G/A, 2026-11-02
• Filing 2026-08-14 · Reporting person: Commodore Capital LP · Sole voting: 0 · Shared voting: 1,511,821 · Sole dispositive: 0 · Shared dispositive: 1,511,821 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: Nantahala Capital Management, LLC · Sole voting: 0 · Shared voting: 1,079,843 · Sole dispositive: 0 · Shared dispositive: 1,079,843 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-14 · Reporting person: OrbiMed Advisors LLC · Sole voting: 0 · Shared voting: 756,860 · Sole dispositive: 0 · Shared dispositive: 756,860 · SCHEDULE 13G, 2026-08-14
• Filing 2026-08-13 · Reporting person: Soleus Capital Master Fund, L.P. · Sole voting: 0 · Shared voting: 679,200 · Sole dispositive: 0 · Shared dispositive: 679,200 · SCHEDULE 13G/A, 2026-08-13

Immunic, Inc. has 33 Schedule 13D or 13G filings on record since 2025-07-31. 13 holders' latest filing reports 5% or more of common stock, par value $0.0001. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Immunic, Inc. and the warning signs.

See Immunic, Inc.'s free Snapshot Watch Immunic, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Immunic, Inc. and the records around it.

Immunic, Inc. elsewhere on the record

• Leadership changes Sep 2026
• Company profile and every filing Mar 2026
• Form D filing Mar 2026
• Who owns it

Companies that share a holder

• Laurion Capital Management LP also filed stake reports on 2 other companies: Pyxis Oncology, Inc. (Nov 2026), Rallybio Corp (Aug 2026)
• Avidity Partners Management LP also filed stake reports on 5 other companies: Context Therapeutics Inc. (May 2026), Perspective Therapeutics, Inc. (Mar 2026), Scynexis, Inc. (Feb 2026)
• Soleus Private Equity Fund III, L.P. also filed stake reports on 5 other companies: Prelude Therapeutics Inc (Jul 2026), CALCIMEDICA, INC. (May 2026), Aprea Therapeutics, Inc. (Apr 2026)

Want the whole picture on Immunic, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Immunic, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Immunic, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   42 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Immunic, Inc. by CUSIP 4525EP200 and gives its principal executive office as 1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK, NY 10036 (SCHEDULE 13G/A, 2026-11-02).

Purpose of Transaction (Item 4)

Biotechnology Value Fund L P

The Reporting Persons purchased the securities reported owned herein based on the Reporting Persons' belief that such securities, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of Shares at prices that would make the purchase or sale of Shares desirable, the Reporting Persons may endeavor to increase or decrease their position in the Issuer through, among other things, the purchase or sale of Shares on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable. Securities Purchase Agreement On February 12, 2026, the Issuer and certain accredited investors (the "Investors"), including certain of the Reporting Persons, entered into a securities purchase agreement (the "Securities Purchase Agreement") pursuant to which the Issuer agreed to sell and issue to the Investors in a private placement (the "Offering"), pre-funded warrants (the "2026 Pre-Funded Warrants") to purchase Shares, with each 2026 Pre-Funded Warrant accompanied by a warrant (the "Common Warrants") to purchase (i) a Share or (ii) a 2026 Pre-Funded Warrant, at a purchase price of $0.873120 per 2026 Pre-Funded Warrant and accompanying Common Warrant. The Offering closed (the "Closing") on February 17, 2026 (the "Closing Date"). In connection with the Closing, BVF, BVF2, …The first part of Item 4 of the SCHEDULE 13D filed 2026-02-20; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Immunic, Inc.

Who owns Immunic, Inc.?

On this page, 13 holders' latest ownership filings report 5% or more of Immunic, Inc.: Adage Capital Management, L.P. (9.99%, Schedule 13G/A, filed 2025-08-12), Biotechnology Value Fund L P (9.99%, Schedule 13D, filed 2026-02-20), Janus Henderson Group Plc (9.99%, Schedule 13G, filed 2025-12-08), Vivo Opportunity Fund Holdings, L.P. (9.99%, Schedule 13G, filed 2026-02-20) and Avidity Partners Management LP (9.9%, Schedule 13G, filed 2026-04-17); 8 more are listed above.

Who are the largest shareholders of Immunic, Inc.?

By the share each holder's latest filing reports, the largest holders of Immunic, Inc. on this page are Adage Capital Management, L.P. (9.99%), Biotechnology Value Fund L P (9.99%) and Janus Henderson Group Plc (9.99%).

When did Adage Capital Management, L.P. buy into Immunic, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Adage Capital Management, L.P. on this page is the Schedule 13G/A, filed 2025-08-12, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 33 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Immunic, Inc.

Swipe the table sideways to see every column.

Immunic, Inc.: every filing and event

Tools for this story

Each opens in a new tab, filled in for Immunic, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Immunic, Inc. is mentioned again
• Find former Immunic, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes